The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Somatic mutations affect key pathways in lung adenocarcinoma
Open accessAbstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While gain of 7p and loss of 8p have been previously reported to occur specifically in EGFR mutated adenocarcinomas16, 17, gain of 16p was a novel association.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [22]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Similarly, mutations in ERBB4 were identified in cancer, particularly melanoma (Prickett et al., 2009), lung adenocarcinoma (Ding et al., 2008), and medulloblastoma (Gilbertson et al., 2001).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ding et al., 2008
In the citing paper
“Gain/amplification of the mutant EGFR allele has previously been reported to frequently occur in LAC and is known to drive tumor progression17.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Cited by
Sorted by citations
Items 901–1,000 of 1,007
Konen, J. M., Wilkinson, S. C., Lee, B., Fu, H., Zhou, W., Jiang, Y., & Marcus, A. I. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-08-0569 · Cited by 46
LKB1 controls inflammatory potential through CRTC2-dependent histone acetylation
Compton, S. E., Kitchen-Goosen, S. M., DeCamp, L. M., Lau, K. H., Mabvakure, B. M., Vos, M., Williams, K. S., Wong, K., Shi, X., Rothbart, S. B., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.04.017 · Cited by 48
Self-citationSchneeberger, V. E., Ren, Y., Luetteke, N., Huang, Q., Chen, L., Lawrence, H. R., Lawrence, N. J., Haura, E. B., Koomen, J. M., Coppola, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3356 · Cited by 49
Self-citationFibroblast Growth Factor Signaling in Non–Small-Cell Lung Cancer
Semrad, T. J., & Mack, P. C. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.001 · Cited by 48
Vescovo, V. D., Cantaloni, C., Cucino, A., Girlando, S., Silvestri, M., Bragantini, E., Fasanella, S., Cuorvo, L. V., Palma, P., Rossi, G., et al. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182068171 · Cited by 47
Regulation of DNA Polymerase POLD4 Influences Genomic Instability in Lung Cancer
Huang, Q. M., Tomida, S., Masuda, Y., Arima, C., Cao, K., Kasahara, T.-A., Osada, H., Yatabe, Y., Akashi, T., Kamiya, K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0784 · Cited by 47
Meguid, R. A., Hooker, C. M., Harris, J., Li, X., Westra, W. H., Sherwood, J. T., Sussman, M. S., Cattaneo, S. M., Shin, J., Cox, S. E., et al. (2010) · CHEST Journal · doi:10.1378/chest.08-2991 · Cited by 47
PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion
Bonastre, E., Verdura, S., Zondervan, I., Facchinetti, F., Lantuéjoul, S., Chiara, M., Rodrigo, J. P., Carretero, J., Condom, E., Vidal, A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2444 · Cited by 47
Jang, J. S., Lee, A. M., Li, J., Liyanage, H., Yang, Y., Guo, L., Asmann, Y. W., Li, P. W., Erickson‐Johnson, M. R., Sakai, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep09755 · Cited by 48
MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations
Hua, X., Hyland, P. L., Huang, J. L., Song, L., Zhu, B., Caporaso, N. E., Landi, M. T., Chatterjee, N., & Shi, J. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.12.021 · Cited by 45
Zhou, J., Zhang, S., Chen, X., Zheng, X., Yao, Y., Lu, G., & Zhou, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.031 · Cited by 47
Wang, Y., Li, N., Jiang, W., Deng, W., Ye, R., Cai, X., Qiao, Y., Sharma, A., Zhang, M., Hung, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1489 · Cited by 46
Role of genomic instability in human carcinogenesis
Moon, J. J., Lu, A., & Moon, C. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219826031 · Cited by 48
Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma
Deng, H., Liu, H., de Silva, T., Xue, Y. C., Mohamud, Y., Ng, C. S., Qu, J., Zhang, J., Jia, W. W.-G., Lockwood, W. W., et al. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.07.003 · Cited by 48
Protein-altering germline mutations implicate novel genes related to lung cancer development
Ji, X., Mukherjee, S., Landi, M. T., Bossé, Y., Joubert, P., Zhu, D. K., Gorlov, I. P., Xiao, X., Han, Y., Gorlova, O. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15905-6 · Cited by 47
Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma
Wagner, P. L., Stiedl, A., Wilbertz, T., Petersen, K., Scheble, V. J., Menon, R., Reischl, M., Mikut, R., Rubin, M. A., Fend, F., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.029 · Cited by 47
Zhang, J., Zhang, S., Wang, Y., & Zhang, X. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-s2-s4 · Cited by 47
Heightening Energetic Stress Selectively Targets LKB1-Deficient Non–Small Cell Lung Cancers
Momcilovic, M., McMickle, R., Abt, E., Seki, A., Simko, S. A., Magyar, C., Stout, D. B., Fishbein, M. C., Walser, T. C., Dubinett, S. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0797 · Cited by 46
“LKB1 mutations either alone or in combination with KRAS occur frequently in NSCLC and constitute a large patient population that would likely benefit from the personalized therapies we have outlined (6, 43).”
Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
Alam, M., Hasan, G. M., Eldin, S. M., Adnan, M., Riaz, M. B., Islam, A., Khan, I., & Hassan, M. I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114452 · Cited by 52
Tumor Suppressors and Cell-Cycle Proteins in Lung Cancer
Baldi, A., Luca, A. D., Esposito, V., Campioni, M., Spugnini, E. P., & Citro, G. (2011) · Pathology Research International · doi:10.4061/2011/605042 · Cited by 45
Personalized targeted therapy in advanced non–small cell lung cancer
Ma, P. C. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79.s2.12 · Cited by 46
Aberrant Expression and Mutation-Inducing Activity of AID in Human Lung Cancer
Shinmura, K., Igarashi, H., Goto, M., Tao, H., Yamada, H., Matsuura, S., Tajima, M., Matsuda, T., Yamane, A., Funai, K., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1568-8 · Cited by 46
Comprehensive analysis of the genome transcriptome and proteome landscapes of three tumor cell lines
Akan, P., Alexeyenko, A., Costea, P. I., Hedberg, L., Solnestam, B. W., Lundin, S., Hällman, J., Lundberg, E. K., Uhlén, M., & Lundeberg, J. (2012) · Genome Medicine · doi:10.1186/gm387 · Cited by 49
Brown, J. B., Cheresh, P., Goretsky, T., Managlia, E. Z., Grimm, G. R., Ryu, H., Zadeh, M., Dirisina, R., & Barrett, T. A. (2011) · Infection and Immunity · doi:10.1128/iai.01025-10 · Cited by 46
Lung Cancer in Never Smokers: A Call to Action
Rudin, C. M., Ávila-Tang, É., & Samet, J. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0373 · Cited by 50
ATM protein is deficient in over 40% of lung adenocarcinomas
Villaruz, L. C., Jones, H., Đačić, S., Abberbock, S. R., Kurland, B. F., Stabile, L. P., Siegfried, J. M., Conrads, T. P., Smith, N. R., O’Connor, M. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9757 · Cited by 46
An Entropy-Based Method for Identifying Mutual Exclusive Driver Genes in Cancer
Song, J., Peng, W., & Wang, F. (2019) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2019.2897931 · Cited by 46
Xu, S., Zheng, Y., Zhang, L., Wang, P., Niu, C., Wu, T., Tian, Q., Yin, X., Shi, S., Zheng, L., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.08.005 · Cited by 46
Burrows, A. C., Prokop, J., & Summers, M. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.390328 · Cited by 46
Ray, R., Khashali, H. A., Haddad, B., Wareham, J., Coleman, K.-L., Alomari, D., Ranzenberger, R., Guthrie, J. W., Heyl, D., & Evans, H. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112829 · Cited by 44
Dervovic, D., Malik, A., Chen, E. L. Y., Narimatsu, M., Adler, N., Afiuni‐Zadeh, S., Krenbek, D., Martinez, S., Tsai, R., Boucher, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38841-7 · Cited by 48
α7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?
Paleari, L., Cesario, A., Fini, M., & Russo, P. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.016 · Cited by 45
Bañón‐Rodríguez, I., Gálvez-Santisteban, M., Vergarajauregui, S., Bosch‐Fortea, M., Borreguero-Pascual, A., & Martín‐Belmonte, F. (2014) · The EMBO Journal · doi:10.1002/embj.201385946 · Cited by 45
Gross, A. M., Kreisberg, J. F., & Ideker, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142618 · Cited by 44
Peng, J., Wang, Q., Liu, H., Ye, M., Wu, X., & Guo, L. (2016) · Tumor Biology · doi:10.1007/s13277-016-5048-4 · Cited by 45
Nielsen, A., & Gjerstorff, M. F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060890 · Cited by 45
The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy
Cummings, C., Peters, E. J., Lacroix, L., André, F., & Lackner, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12429 · Cited by 47
HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer
Sugita, S., Enokida, H., Yoshino, H., Miyamoto, K., Yonemori, M., Sakaguchi, T., Osako, Y., & Nakagawa, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4435 · Cited by 47
ATM Mediates pRB Function To Control DNMT1 Protein Stability and DNA Methylation
Shamma, A., Suzuki, M., Hayashi, N., Kobayashi, M., Sasaki, N., Nishiuchi, T., Doki, Y., Okamoto, T., Kohno, S., Muranaka, H., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01597-12 · Cited by 45
Grabauskiene, S., Bergeron, E. J., Chen, G., Chang, A. C., Lin, J., Thomas, D. G., Giordano, T. J., Beer, D. G., Morgan, M. A., & Reddy, R. M. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.09.010 · Cited by 44
Self-citationKubo, T., Kuroda, Y., Shimizu, H., Kokubu, A., Okada, N., Hosoda, F., Arai, Y., Nakamura, Y., Taniguchi, H., Yanagihara, K., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp206 · Cited by 45
MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Smida, M., Fece de la Cruz, F., Kerzendorfer, C., Uras, I. Z., Mair, B., Mazouzi, A., Suchankova, T., Konopka, T., Katz, A. M., Paz, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13701 · Cited by 44
“The high frequency of ATM mutation in this collection (12 out of 93 cell lines, Supplementary Dataset 2) was similar to that previously reported in patients 2,4,5 .”
InfluentialKrishnan, V. G., Ebert, P. J., Ting, J. C., Lim, E. H., Wong, S. S., Teo, A. S. M., Yue, Y. G., Chua, H.-H., Ma, X., Loh, G. S. L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3195 · Cited by 45
Stein, B. D., Ferrarone, J. R., Gardner, E. E., Chang, J. W., Wu, D., Hollstein, P. E., Liang, R. J., Yuan, M., Chen, Q., Coukos, J. S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0805 · Cited by 45
Self-citationPrognostic and predictive biomarkers in non-small cell lung carcinoma
Odintsov, I., & Sholl, L. M. (2023) · Pathology · doi:10.1016/j.pathol.2023.11.006 · Cited by 47
Targeted High-Throughput DNA Sequencing for Gene Discovery in Retinitis Pigmentosa
Daiger, S. P., Sullivan, L. S., Bowne, S. J., Birch, D. G., Heckenlively, J. R., Pierce, E. A., & Weinstock, G. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1399-9_37 · Cited by 44
Self-citationMicrofluidic droplet enrichment for targeted sequencing
Eastburn, D. J., Huang, Y., Pellegrino, M., Sciambi, A., Ptáček, L. J., & Abate, A. R. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv297 · Cited by 44
Shilo, A., Siegfried, Z., & Karni, R. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.970955 · Cited by 45
Lung adenocarcinoma subtypes based on expression of human airway basal cell genes
Fukui, T., Shaykhiev, R., Agosto-Perez, F., Mezey, J. G., Downey, R. J., Travis, W. D., & Crystal, R. G. (2013) · European Respiratory Journal · doi:10.1183/09031936.00144012 · Cited by 44
Self-citationSHP2E76K mutant promotes lung tumorigenesis in transgenic mice
Schneeberger, V. E., Luetteke, N., Ren, Y., Berns, H., Chen, L., Foroutan, P., Martinez, G. V., Haura, E. B., Chen, J., Coppola, D., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu025 · Cited by 44
Self-citationChemoprevention of Lung Cancer
Keith, R. L. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200807-067lc · Cited by 44
Yeddula, N., Xia, Y., Ke, E., Beumer, J., & Verma, I. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520110112 · Cited by 43
FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies
Weeden, C. E., Solomon, B., & Asselin-Labat, M.-L. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.49 · Cited by 44
Integration of multiple networks and pathways identifies cancer driver genes in pan-cancer analysis
Cava, C., Bertoli, G. R., Colaprico, A., Olsen, C., Bontempi, G., & Castiglioni, I. (2018) · BMC Genomics · doi:10.1186/s12864-017-4423-x · Cited by 43
Deng, S., Clowers, M. J., Velasco, W. V., Ramos-Castaneda, M. A., & Moghaddam, S. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01556 · Cited by 45
Ahmed, E. Y., Elserwy, W. S. G., El‐Mansy, M. F., Serry, A. M., Salem, A. M., Abdou, A. M., Abdelrahman, B. A., Elsayed, K. H., & Elaziz, M. R. A. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128258 · Cited by 44
Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer
Rosellini, P., Amintas, S., Caumont, C., Veillon, R., Galland-Girodet, S., Cuguillière, A., Nguyen, L., Domblides, C., Gouverneur, A., Merlio, J.-P., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.026 · Cited by 44
Induction of Lung Tumors in Mice with UrethanePreprint
Gurley, K. E., Moser, R. D., & Kemp, C. J. (2015) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot077446 · Cited by 44
Tan, D. S. W., Camilleri‐Broët, S., Tan, E. H., Alifano, M., Lim, W., Bobbio, A., Zhang, S., Ng, Q., Ang, M., Iyer, N. G., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28750 · Cited by 43
D’Antonio, M., Pendino, V., Sinha, S., & Ciccarelli, F. D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr952 · Cited by 41
Gutierrez, E., Cahatol, I., Bailey, C., Lafargue, A. M., Zhang, N., Song, Y., Tian, H., Zhang, Y., Chan, R., Gu, K., et al. (2019) · Cancers · doi:10.3390/cancers11060818 · Cited by 43
Structural Analysis of the Human Fibroblast Growth Factor Receptor 4 Kinase
Lesca, E., Lammens, A., Huber, R., & Augustin, M. A. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.004 · Cited by 43
Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack
Henderson, D. A., Ogilvie, L. A., Hoyle, N. R., Keilholz, U., Lange, B. M. H., & Lehrach, H. (2014) · Biotechnology Journal · doi:10.1002/biot.201400109 · Cited by 44
Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis
Schuster, K., Venkateswaran, N., Rabellino, A., Girard, L., Peña‐Llopis, S., & Scaglioni, P. P. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0620-t · Cited by 43
Neurofibromatosis type 1: diagnosis and recent advances
Upadhyaya, M. (2010) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2010.494660 · Cited by 43
Sanders, E. B., & Diehl, S. (2015) · Oncoscience · doi:10.18632/oncoscience.128 · Cited by 43
Zhao, J., Liu, J., Lee, J.-F., Zhang, W., Kandouz, M., VanHecke, G. C., Chen, S., Ahn, Y., Lonardo, F., & Lee, M.-J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.740084 · Cited by 45
Treating KRAS -mutant NSCLC: latest evidence and clinical consequences
Garrido, P., Olmedo, M. E., Gómez, A., Ares, L. P., López‐Ríos, F., Rosa-Rosa, J. M., & Palacios, J. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017719829 · Cited by 45
In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer
Grzeskowiak, C. L., Kundu, S. T., Mo, X., Ivanov, A. A., Zagorodna, O., Lu, H., Chapple, R. H., Tsang, Y. H., Moreno, D., Mosqueda, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04572-3 · Cited by 44
Self-citationAuranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Hu, J., Zhang, H., Cao, M., Wang, L., Wu, S., & Fang, B. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1173 · Cited by 46
Zhang, H., Guo, L., & Chen, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s248436 · Cited by 45
The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment
Sato, T., & Gotoh, N. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942330 · Cited by 43
Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2
Mikawa, T., Maruyama, T., Okamoto, K., Nakagama, H., LLeonart, M. E., Tsusaka, T., Hori, K., Murakami, I., Izumi, T., Takaori‐Kondo, A., et al. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201306149 · Cited by 45
Radon-Induced Alterations in Micro-RNA Expression Profiles in Transformed BEAS2B Cells
Cui, F., Li, J., Qiu, C., Du, H.-B., Zhang, S., Nie, J., Cao, J., Zhou, P., Hei, T. K., & Tong, J. (2013) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2013.738176 · Cited by 43
Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model
Lyon, C. M., Klinge, D. M., Do, K. C., Grimes, M. J., Thomas, C. L., Damiani, L. A., March, T. H., Stidley, C. A., & Belinsky, S. A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp260 · Cited by 43
TP53 alterations of hormone-naïve prostate cancer in the Chinese population
Liu, Z., Guo, H., Zhu, Y., Xia, Y., Cui, J., Shi, K., Fan, Y., Shi, B., & Chen, S. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00302-3 · Cited by 41
Self-citationThe Tumor Suppressor Kinase LKB1: Metabolic Nexus
Bourouh, M., & Marignani, P. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.881297 · Cited by 48
Roper, J., Sinnamon, M. J., Coffee, E. M., Belmont, P. J., Keung, L., Richard, L. G., Wang, W. V., Faber, A. C., Yun, J., Yilmaz, Ö. H., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.018 · Cited by 42
Suzuki, A., Mimaki, S., Yamane, Y., Kawase, A., Matsushima, K., Suzuki, M., Goto, K., Sugano, S., Esumi, H., Suzuki, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073484 · Cited by 43
BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer
Rodrı́guez-Nieto, S., & Sánchez‐Céspedes, M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp035 · Cited by 44
Ishikawa, M., Miyahara, R., Sonobe, M., Horiuchi, M., Mennju, T., Nakayama, E., Kobayashi, M., Kikuchi, R., Kitamura, J., Imamura, N., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.004 · Cited by 42
Muller, I. B., Langen, A. J. D., Honeywell, R. J., Giovannetti, E., & Peters, G. J. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1131612 · Cited by 44
Cat Mammary Tumors: Genetic Models for the Human Counterpart
Adega, F., Borges, A., & Chaves, R. (2016) · Veterinary Sciences · doi:10.3390/vetsci3030017 · Cited by 48
Cassidy, R. J., Zhang, X., Patel, P. R., Shelton, J. W., Escott, C., Sica, G., Rossi, M. R., Hill, C. E., Steuer, C. E., Pillai, R. N., et al. (2017) · Cancer · doi:10.1002/cncr.30794 · Cited by 43
Hermelijn, S. M., Wolf, J. L., den Toom, T. D., Wijnen, R. M. H., Rottier, R. J., Schnater, J. M., & von der Thüsen, J. H. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.07.015 · Cited by 43
Xu, Q., Wang, C., Zhou, J., Xu, Z.-M., Gao, J., Sui, P., Walsh, C. P., Ji, H., & Xu, G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107599119 · Cited by 41
The Mutator Phenotype in Cancer: Molecular Mechanisms and Targeting Strategies
Prindle, M. J., Fox, E., & Loeb, L. A. (2010) · Current Drug Targets · doi:10.2174/1389450111007011296 · Cited by 43
Lung cancer in never smokers: Tumor immunology and challenges for immunotherapy
de Alencar, V. T. L., Figueiredo, A. B., Corassa, M. P., Gollob, K. J., & de Lima, V. C. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984349 · Cited by 47
Delving into somatic variation in sporadic melanoma
Walia, V., Mu, E. W., Lin, J., & Samuels, Y. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00976.x · Cited by 41
Molecular Testing of Solid Tumors
Igbokwe, A., & Lopez-Terrada, D. H. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0413-rar.1 · Cited by 38
Garrido, P., de Castro, J., Concha, Á., Felip, E., Isla, D., López‐Ríos, F., Paz-Ares, L. G., Ramírez, J., Sanz‐Ortega, J., & Gómez‐Román, J. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0806-2 · Cited by 41
Targeted Therapies in Lung Cancer
Chirieac, L. R., & Đačić, S. (2010) · Surgical pathology clinics · doi:10.1016/j.path.2010.04.001 · Cited by 41
Self-citationHomotypic receptor-receptor interactions regulating Eph signaling
Nikolov, D. B., Xu, K. Y., & Himanen, J. P. (2014) · Cell Adhesion & Migration · doi:10.4161/19336918.2014.971684 · Cited by 41
Curry, N. L., Mino-Kenudson, M. A., Oliver, T. G., Yilmaz, Ö. H., Yilmaz, V. O., Moon, J. Y., Jacks, T., Sabatini, D. M., & Kalaany, N. Y. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0507 · Cited by 42
Energy sensing and cancer: LKB1 function and lessons learnt from Peutz–Jeghers syndrome
Shorning, B. Y., & Clarke, A. R. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.02.015 · Cited by 45
Deb, D., Rajaram, S., Larsen, J. E., Dospoy, P. D., Marullo, R., Li, L. S., Avila, K., Xue, F., Cerchietti, L. C. A., Minna, J. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3052 · Cited by 41
Abravanel, D. L., Nishino, M., Sholl, L. M., Ambrogio, C., & Awad, M. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.026 · Cited by 42
Vernieri, C., Signorelli, D., Galli, G., Ganzinelli, M., Moro, M., Fabbri, A., Tamborini, E., Marabese, M., Caiola, E., Broggini, M., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.011 · Cited by 41
Fiala, O., Pešek, M., Fínek, J., Minárik, M., Benešová, L., Bortlíček, Z., & Topolčan, O. (2015) · Tumor Biology · doi:10.1007/s13277-015-3249-x · Cited by 41
Squamous Transition of Lung Adenocarcinoma and Drug Resistance
Hou, S., Han, X., & Ji, H. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.08.002 · Cited by 34
Metadata
- Authors
- Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., & Wilson, R. K.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Max Planck Society (DE)
- University of Michigan (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Meyerson, Matthew
- Wilson, Richard K.
- ORCID
- Ding, Li
- Getz, Gad
- Wheeler, David A.
- Mardis, Elaine R.
- McLellan, Michael D.
- Cibulskis, Kristian
- Greulich, Heidi
- Muzny, Donna M.
- Morgan, Margaret B.
- Fulton, Lucinda
- Fulton, Robert S.
- Wendl, Michael C.
- Lawrence, Michael S.
- Larson, David E.
- Chen, Ken
- Sabo, Aniko
- Shen, Hua
- Jhangiani, Shalini N.
- Zhu, Yiming
- Ren, Yanru
- Yao, Jiqiang
- Scherer, Steven E.
- Metcalf, Ginger A.
- Ng, Brian
- Milosavljevic, Aleksandar
- Tang, Yuzhu
- Koboldt, Daniel C.
- Lin, Ling
- Pohl, Craig
- Crosby, Seth D.
- Vickery, Tammi
- Winckler, Wendy
- Chirieac, Lucian R.
- Dutt, Amit
- Fennell, Tim
- Johnson, Bruce E.
- Thomas, Roman K.
- Tonon, Giovanni
- Zody, Michael C.
- Giordano, Thomas
- Roth, Jack A.
- Wistuba, Ignacio I.
- Ozenberger, Bradley
- Chang, Andrew C.
- Beer, David G.
- Watson, Mark A.
- Ladanyi, Marc
- Broderick, Stephen
- Yoshizawa, Akihiko
- Travis, William D.
- Pao, William
- Province, Michael A.
- Weinstock, George M.
- Varmus, Harold E.
- Gabriel, Stacey B.
- Lander, Eric S.
- Gibbs, Richard A.
- Meyerson, Matthew
- Wilson, Richard K.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7216
- Pages
- 1069-1075
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2694412
- OpenAlex
- W2163798887
- Cited by
- 2,681
- References
- 54
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 53 · 2023: 122 · 2022: 124 · 2021: 149 · 2020: 147 · 2019: 145 · 2018: 121 · 2017: 141 · 2016: 158 · 2015: 206 · 2014: 254 · 2013: 213 · 2012: 227
- FWCI
- 167.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U19CA084953, P50CA070907, R01CA154365)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, carcinogenesis, tyrosine kinase, EphA3, Eph receptors, KDR, NTRK, tumor suppressor, neurofibromatosis type 1, APC, RB1, ATM, PTPRD, LRP1B, smoking, DNA repair deficiency, signaling pathways, molecular targets, mutational landscape
- MeSH terms
- Adenocarcinoma, Bronchiolo-Alveolar, Female, Humans, Lung Neoplasms, Male, Mutation, Proto-Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Gene Dosage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
